Nov 14: Hyderabad-based drug maker Dr Reddy’s Laboratories Ltd on Tuesday announced that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar (Clofarabine) Injection in the United States market, approved by the US Food and Drug Administration (USFDA).
Clolar is a registered trademark of American biotechnology firm Genzyme Corporation. The Clolar brand and generic had US sales of approximately $53 million MAT for the most recent twelve months ended in September 2017, according to IMS Health.
Dr Reddy’s Laboratories Clofarabine Injection is available in single dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1 mg/mL).
Dr Reddy’s shares were trading in red at Rs 2,339.95, down 0.18% from the previous closing of Rs 2,344.15, on BSE at 1.48 pm today.